PE20031010A1 - Derivados de tiazol y oxazol que modulan la actividad de ppar - Google Patents

Derivados de tiazol y oxazol que modulan la actividad de ppar

Info

Publication number
PE20031010A1
PE20031010A1 PE2003000214A PE2003000214A PE20031010A1 PE 20031010 A1 PE20031010 A1 PE 20031010A1 PE 2003000214 A PE2003000214 A PE 2003000214A PE 2003000214 A PE2003000214 A PE 2003000214A PE 20031010 A1 PE20031010 A1 PE 20031010A1
Authority
PE
Peru
Prior art keywords
ilmethylsulfanil
iloxi
thazol
trifluoromethyl
phenyl
Prior art date
Application number
PE2003000214A
Other languages
English (en)
Inventor
xue-ming Cheng
Noe Ouano Erasga
Bharat Kalidas Trivedi
Andrew George Geyer
Chitase Lee
Gary Frederick Filzen
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20031010A1 publication Critical patent/PE20031010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A DERIVADOS DE TIAZOL Y OXAZOL DE FORMULA I DONDE T ES UNA CADENA DE HIDROCARBURO CON HETEROATOMOS DE 3 A 6, EN LA QUE EL ATOMO DE CARBONO DE LA POSICION 2 ESTA CONECTADO AL ATOMO DE CARBONO DE LA POSICION 3 PARA FORMAR UN ANILLO DE 5 A 8 MIEMBROS; W ES O, S, CH2, CR4R5, NR3, CICLOALQUILENO, HETEROCICLOALQUILENO; Y ESTA AUSENTE, O, CR4R5 EN EL QUE Y ES CR4R5 ESTA AUSENTE CUANDO W ES O, S, NR3; R1 Y R2 SON H, ALQUILO, ALCOXI, HALOALQUILO, -O-(CH2)pCF3, HALOGENO, NITRO, CIANO, OH, SH, CFE, S(O)pALQUILO, ENTRE OTROS; R3 ES H, ALQUILO, ALQUENILO, ALQUINILO; R4 Y R5 SON H, ALQUILO, ALQUENILO, ALQUINILO, ARILO, ENTRE OTROS; R6 Y R7 SON H, ALQUILO, ALQUENILO, ALQUINILO, -COALQUILO, -COARILO, ENTRE OTROS; X0 Y X1 SON O, S; AR1 ES ARILO, HETEROARILO, m ES 0-5; n ES 0-5; p ES 0-2. SON COMPUESTOS PREFERIDOS ACIDO {4-[4-METIL-2-(4-TRIFLUOROMETIL-FENIL)-TIAZOL-5-ILMETILSULFANIL]-5-OXO-5,6,7,8-TETRAHIDRO-NAFTALEN-1-ILOXI}-ACETICO, ACIDO {4-[4-METIL-2-(4-TRIFLUOROMETIL-FENIL)-TIAZOL-5-ILMETILSULFANIL]-8-OXO-5,6,7,8-TETRAHIDRO-NAFTALEN-1-ILOXI}-ACETICO, ACIDO {4-[4-METIL-2-(4-TRIFLUOROMETIL-FENIL)-TIAZOL-5-ILMETILSULFANIL]-7-OXO-5,6,7,8-TETRAHIDRO-NAFTALEN-1-ILOXI}-ACETICO, ACIDO {4-[4-METIL-2-(4-TRIFLUOROMETIL-FENIL)-TIAZOL-5-ILMETILSULFANIL]-4-OXO4H-CROMEN-8-ILOXI}-ACETICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON UTILES PARA EL TRATAMIENTO DE HIPERLIPIDEMEIA, HIPERCOLESTEREMIA
PE2003000214A 2002-03-07 2003-03-05 Derivados de tiazol y oxazol que modulan la actividad de ppar PE20031010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240002P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
PE20031010A1 true PE20031010A1 (es) 2003-12-12

Family

ID=27789156

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000214A PE20031010A1 (es) 2002-03-07 2003-03-05 Derivados de tiazol y oxazol que modulan la actividad de ppar

Country Status (29)

Country Link
US (1) US6833380B2 (es)
EP (1) EP1485091A1 (es)
JP (1) JP2005524665A (es)
KR (1) KR20040091694A (es)
CN (1) CN1638768A (es)
AP (1) AP2004003123A0 (es)
AR (1) AR038883A1 (es)
AU (1) AU2003207891A1 (es)
BR (1) BR0308221A (es)
CA (1) CA2476580A1 (es)
CO (1) CO5601013A2 (es)
EA (1) EA200401160A1 (es)
EC (1) ECSP045275A (es)
GT (1) GT200300053A (es)
HR (1) HRP20040810A2 (es)
IL (1) IL163768A0 (es)
IS (1) IS7399A (es)
MA (1) MA27182A1 (es)
MX (1) MXPA04008624A (es)
NO (1) NO20044245L (es)
OA (1) OA12781A (es)
PA (1) PA8568701A1 (es)
PE (1) PE20031010A1 (es)
PL (1) PL372971A1 (es)
TN (1) TNSN04167A1 (es)
TW (1) TW200400027A (es)
UY (1) UY27704A1 (es)
WO (1) WO2003074052A1 (es)
ZA (1) ZA200406491B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
JP4981662B2 (ja) 2004-05-05 2012-07-25 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規の化合物、その製法と使用
CA2567437A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
JP2008500358A (ja) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
EP2205565B1 (en) 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU708055B2 (en) 1996-02-02 1999-07-29 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
CN1233241A (zh) 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP2003508389A (ja) 1999-08-27 2003-03-04 エリ リリー アンド カンパニー ビアリール−オキサ（チア）ゾール誘導体およびそのｐｐａｒモジュレーターとしての使用
SK1872003A3 (en) 2000-08-23 2003-07-01 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
EP1345916A1 (en) 2000-12-20 2003-09-24 Glaxo Group Limited Substituted oxazoles and thiazoles as hppar alpha agonists
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
EP1398313A4 (en) 2001-05-29 2005-11-16 Kyoto Pharma Ind NEW HETEROCYCLIC DERIVATIVES AND THEIR MEDICAL USE
US7282501B2 (en) 2001-06-07 2007-10-16 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (PPAR)
US6924295B2 (en) 2001-06-18 2005-08-02 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
IL160845A0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
MXPA04008624A (es) 2004-12-06
ZA200406491B (en) 2006-05-31
OA12781A (en) 2006-07-07
GT200300053A (es) 2003-10-10
AP2004003123A0 (en) 2004-09-30
PL372971A1 (en) 2005-08-08
US6833380B2 (en) 2004-12-21
NO20044245L (no) 2004-10-06
BR0308221A (pt) 2005-01-04
IL163768A0 (en) 2005-12-18
ECSP045275A (es) 2004-10-26
AR038883A1 (es) 2005-02-02
AU2003207891A1 (en) 2003-09-16
JP2005524665A (ja) 2005-08-18
CO5601013A2 (es) 2006-01-31
HRP20040810A2 (en) 2004-12-31
TNSN04167A1 (fr) 2007-03-12
TW200400027A (en) 2004-01-01
KR20040091694A (ko) 2004-10-28
WO2003074052A1 (en) 2003-09-12
MA27182A1 (fr) 2005-01-03
IS7399A (is) 2004-08-12
EP1485091A1 (en) 2004-12-15
US20030207916A1 (en) 2003-11-06
CN1638768A (zh) 2005-07-13
PA8568701A1 (es) 2003-11-12
CA2476580A1 (en) 2003-09-12
UY27704A1 (es) 2003-10-31
EA200401160A1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
PE20031010A1 (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
PE20030989A1 (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
PE20040190A1 (es) Tiazoles y oxazoles sustituidos que modulan la actividad de ppar
PE20020100A1 (es) DERIVADOS DE 2-SULFONIL AMINO-1,3-TIAZOL COMO INHIBIDORES DE 11-ß-HIDROXI ESTEROIDE DESHIDROGENASA TIPO 1 (11ßHSD1)
PE20021152A1 (es) Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma
PE20010529A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
PE20011313A1 (es) Activadores de glucoquinasa que contienen hidantoina
PE20020504A1 (es) N-acilsulfonamidas promotoras de apoptosis
PE20050147A1 (es) Derivados de pirimidina, piridina y tiazol como inhibidores de fosfatidilinositol 3-quinasa
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20040844A1 (es) Acidos fenilaceticos y derivados como inhibidores de la cox-2
PT97169A (pt) Processo para a preparacao de composicoes farmaceuticas inibidora das enzimas 5-lipxigenase e ciclo-oxigenase contendo derivados de 3,5-di-terc-butil-4-hidroxifenilmetileno de tiazolidinonas, oxazolidinona e imidazolidinonas 2-substituidas
AR039239A1 (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion
CO5251452A1 (es) Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar
PE20001005A1 (es) Benzazoles: derivados de benzoxazol, benzotiazol y bencimidazol
PE20000625A1 (es) Derivados de acido oxiiminoalcanoico
PE20050417A1 (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
PE20020103A1 (es) Derivados de 1-sulfonil-pirrolidina
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
PE20060657A1 (es) Derivados de pirimidina como moduladores de ppar-alfa
PE20011089A1 (es) Tioamidas de oxazolidinona con sustituyentes de piperazin-amida
PE20020253A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano como ligandos de receptores opiaceos
PE20020063A1 (es) Bis-arilsulfonas como ligandos del receptor de 5-ht
KR840006633A (ko) 벤족사졸리논 유도체의 제조방법
PE20050160A1 (es) 3-aminopirrolidinas como inhibidores de la captacion de monoaminas

Legal Events

Date Code Title Description
FD Application declared void or lapsed